Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.

被引：0
|
作者：
Casadei-Gardini, Andrea
Rimini, Margherita
Rimassa, Lorenza
Burgio, Valentina
Kudo, Masatoshi
Tada, Toshifumi
Shimose, Shigeo
Suda, Goki
Yoo, Changhoon
Cheon, Jaekyng
Pinato, David J. James
Scartozzi, Mario
Cascinu, Stefano
机构：
[1] Osped San Raffaele, Milan, Italy
[2] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy
[3] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy
[4] IRCCS San Raffaele, Dept Oncol, Div Expt Med, Milan, Italy
[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osakasayama, Japan
[6] Japanese Red Cross Soc Himeji Hosp, Dept Gastroenterol, Himeji, Hyogo, Japan
[7] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[8] Hokkaido Univ, Sapporo, Hokkaido, Japan
[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[10] CHA Bundang Med Ctr, Seongnam, Japan
[11] Imperial Coll, Dept Surg & Canc, London, England
[12] Univ Hosp, Med Oncol Unit, Cagliari, Italy
[13] Univ Cagliari, Cagliari, Italy
[14] Univ Vita Salute, San Raffaele Hosp, IRCCS, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4069
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
    Rimini, M.
    Rimassa, L.
    Kudo, M.
    Shigeo, S.
    Toshifumi, T.
    Suda, G.
    Yoo, C.
    Cheon, J.
    Lonardi, S.
    Scartozzi, M.
    Tamburini, E.
    Masi, G.
    Cascinu, S.
    Casadei-Gardini, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S362 - S363
  • [2] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
    Rimini, M.
    Rimassa, L.
    Ueshima, K.
    Burgio, V
    Shigeo, S.
    Tada, T.
    Suda, G.
    Yoo, C.
    Cheon, J.
    Pinato, D. J.
    Lonardi, S.
    Scartozzi, M.
    Iavarone, M.
    Di Costanzo, G. G.
    Marra, F.
    Solda, C.
    Tamburini, E.
    Piscaglia, F.
    Masi, G.
    Cabibbo, G.
    Foschi, F. G.
    Silletta, M.
    Pressiani, T.
    Nishida, N.
    Iwamoto, H.
    Sakamoto, N.
    Ryoo, B-Y
    Chon, H. J.
    Claudia, F.
    Niizeki, T.
    Sho, T.
    Kang, B.
    D'Alessio, A.
    Kumada, T.
    Hiraoka, A.
    Hirooka, M.
    Kariyama, K.
    Tani, J.
    Atsukawa, M.
    Takaguchi, K.
    Itobayashi, E.
    Fukunishi, S.
    Tsuji, K.
    Ishikawa, T.
    Tajiri, K.
    Ochi, H.
    Yasuda, S.
    Toyoda, H.
    Ogawa, C.
    Nishimur, T.
    ESMO OPEN, 2022, 7 (06)
  • [3] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Ahmed, Faiza
    Onwumeh-Okwundu, Jennifer
    Yukselen, Zeynep
    Endaya Coronel, Maria-Kassandra
    Zaidi, Madiha
    Guntipalli, Prathima
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1813 - 1832
  • [4] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Faiza Ahmed
    Jennifer Onwumeh-Okwundu
    Zeynep Yukselen
    Maria-Kassandra Endaya Coronel
    Madiha Zaidi
    Prathima Guntipalli
    Vamsi Garimella
    Sravya Gudapati
    Marc Darlene Mezidor
    Kim Andrews
    Mohamad Mouchli
    Endrit Shahini
    World Journal of Gastrointestinal Oncology, 2021, 13 (11) : 1813 - 1832
  • [5] Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
    Rimini, Margherita
    Persano, Mara
    Tada, Toshifumi
    Suda, Goki
    Shigeo, Shimose
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Lonardi, Sara
    Piscaglia, Fabio
    Chon, Hong Jae
    Masi, Gianluca
    Scartozzi, Mario
    Cascinu, Stefano
    Casadei-Gardini, Andrea
    JOURNAL OF HEPATOLOGY, 2023, 78 : S592 - S592
  • [6] SIMILAR EFFICACY AND SAFETY BETWEEN LENVATINIB VERSUS ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Su, Chung-Wei
    Teng, Wei
    Lin, Po-Ting
    Jeng, Wen-Juei
    Chen, Kuei-An
    Hsieh, Yi-Chung
    Chen, Wei-Ting
    Hou, Ming-Mo
    Hsieh, Chia-Hsun
    Lin, Chen-Chun
    Lin, Chun-Yen
    Lin, Hsi-Ming
    HEPATOLOGY, 2022, 76 : S1415 - S1415
  • [7] Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
    Lombardi, P.
    Manfredi, G. F.
    Celsa, C.
    Stefanini, B.
    Marron, T.
    Saeed, A.
    Pinter, M.
    Ulahannan, S.
    Piscaglia, F.
    Lin, C-Y.
    Dalbeni, A.
    Masi, G.
    Schoenlein, M.
    Galle, P. R.
    Kudo, M.
    Rimassa, L.
    Chon, H.
    Pirisi, M.
    Pinato, D. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S666 - S666
  • [8] The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
    Trueman, David
    Liu, Yifeng
    Geadah, Marc
    Hon, Nicholas
    Sabapathy, Suthakar
    Kamboj, Laveena
    Li, Huimin
    Lucero, Melanie
    Meier, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
    Rimini, M.
    Casadei-Gardini, A.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Rimassa, L.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Tovoli, F.
    Cascinu, S.
    Cucchetti, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S1466 - S1466
  • [10] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
12345